title: Bevacizumab and hereditary haemorrhagic telangiectasia.
authors.forename: Ross P
authors.initials: RP
authors.lastname: Cruikshank
authors.forename: Boris W
authors.initials: BW
authors.lastname: Chern
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D012720:Severity of Illness Index; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab